Samsung BioEpis pitches Herceptin biosimilar as parent company hunts $2B IPO; Chiasma CEO is out
In the latest advance by a new wave of biosimilars hitting regulators on both sides of the Atlantic, Samsung Bioepis says that it has filed for a European approval of a knockoff of Herceptin. Bioepis is majority controlled by Samsung BioLogics, which just filed to raise up to $2 billion in an IPO that values the company at more than $8 billion. Biogen owns 8.8% of the company under an earlier deal to partner on development projects.
A few days ago Chiasma announced that CEO Mark Leuchtenberger had left the company “to pursue other opportunities.” He’s being replaced at the helm of the Waltham, MA-based biotech by CFO Mark J. Fitzpatrick. Back in April, the FDA rejected Chiasma’s application for an oral reformulated therapy for acromegaly. The company later restructured, laying off staff, as it sought to find a path forward.
Japan’s Daiichi Sankyo inked a collaboration with AgonOx that will look to develop a pipeline of immunotherapies that target an undisclosed immuno-oncology target. The Portland, OR-based biotech struck a deal to partner with MedImmune with its OX40 platform.
Acorda Therapeutics says that its CFO, Michael Rogers, has left the company. Rogers will serve as a consultant through the end of the year.